United Therapeutics (NASDAQ:UTHR) Cut to Buy at StockNews.com

StockNews.com cut shares of United Therapeutics (NASDAQ:UTHRFree Report) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday.

A number of other brokerages have also commented on UTHR. HC Wainwright reissued a buy rating and set a $300.00 price objective on shares of United Therapeutics in a report on Thursday, May 2nd. Wedbush restated an outperform rating and set a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. Wells Fargo & Company upped their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the company an overweight rating in a research report on Wednesday, June 12th. JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the company an overweight rating in a research report on Tuesday, May 21st. Finally, Oppenheimer upped their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the company an outperform rating in a research report on Thursday, May 2nd. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $312.22.

Read Our Latest Stock Analysis on UTHR

United Therapeutics Stock Up 2.3 %

Shares of NASDAQ:UTHR opened at $316.04 on Thursday. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $317.46. The company’s 50-day moving average price is $266.47 and its two-hundred day moving average price is $241.44. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The firm has a market cap of $14.02 billion, a P/E ratio of 14.94, a P/E/G ratio of 4.60 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHRGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same quarter in the prior year, the firm earned $4.86 EPS. The company’s revenue was up 33.7% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics will post 24.61 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In related news, Director Christopher Causey sold 2,240 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the sale, the director now directly owns 4,185 shares in the company, valued at approximately $1,087,723.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Christopher Causey sold 2,240 shares of the stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the sale, the director now directly owns 4,185 shares in the company, valued at approximately $1,087,723.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $248.33, for a total transaction of $3,724,950.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $32,282.90. The disclosure for this sale can be found here. Insiders have sold 144,728 shares of company stock worth $36,072,597 in the last ninety days. Company insiders own 12.50% of the company’s stock.

Institutional Trading of United Therapeutics

Several hedge funds have recently bought and sold shares of UTHR. Rise Advisors LLC acquired a new stake in United Therapeutics during the 1st quarter worth approximately $32,000. GAMMA Investing LLC bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $43,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares in the last quarter. C M Bidwell & Associates Ltd. bought a new position in shares of United Therapeutics during the 3rd quarter worth approximately $91,000. Finally, Janiczek Wealth Management LLC grew its stake in shares of United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 84 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Stories

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.